Watch BBIO. Know when insiders buy.
One email the day a filing lands. Free.
Work order
38
FLAG · insiders 25, shorts 50
Insiders, 90 days
−$3.7M
net selling · 0 buys, 7 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
2 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $14.6BP/E —DIV YIELD —FCF YIELD -2.98%REV TTM $713.1M +202.4%NET INCOME −$702MNET DEBT $2B52W 49.00 – 90.17NEXT EARNINGS Oct 28 EST.SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $243.7M | +120.4% | 93.8% | −$107.1M | −$155.9M | — | -0.78 | −$71.1M | $443K | −$71.5M | Aug 10 |
| Q1 2026 · Mar 31 | $194.5M | +66.8% | 94.9% | −$106M | −$166.6M | — | -0.84 | −$197.3M | $69K | −$197.3M | May 7 |
| Q4 2025 · Dec 31derived | $154.2M | +2521.2% | 94.7% | −$139.6M | −$194.6M | — | -0.99 | −$56.4M | $33K | −$56.5M | Feb 24 |
| Q3 2025 · Sep 30 | $120.7M | +4318.0% | 94.6% | −$145.2M | −$184.9M | — | -0.95 | −$109.6M | $470K | −$110M | Oct 29 |
| Q2 2025 · Jun 30 | $110.6M | +4999.9% | 96.7% | −$134.3M | −$183.8M | — | -0.95 | −$80.7M | $594K | −$81.3M | Aug 10 |
| Q1 2025 · Mar 31 | $116.6M | −44.8% | 97.7% | −$104.4M | −$169.6M | — | -0.88 | −$199.2M | $0 | −$199.2M | May 7 |
| Q4 2024 · Dec 31derived | $5.9M | +237.1% | 64.6% | −$226M | −$267.4M | — | -1.42 | −$195.3M | $47K | −$195.4M | Feb 24 |
| Q3 2024 · Sep 30 | $2.7M | −33.2% | 78.1% | −$191.8M | −$164.3M | — | -0.86 | −$180.6M | $137K | −$180.7M | Oct 29 |
| Q2 2024 · Jun 30 | $2.2M | — | 72.4% | −$175.5M | −$75.5M | — | -0.39 | $74.7M | $54K | $74.6M | Aug 5 |
| Q1 2024 · Mar 31 | $211.1M | — | 99.7% | $343K | −$36.2M | — | -0.20 | −$219.5M | $695K | −$220.2M | Apr 29 |
| Q4 2023 · Dec 31derived | $1.7M | — | 65.7% | −$177.4M | −$170.3M | — | -0.96 | −$124.8M | $435K | −$125.3M | Feb 24 |
| Q3 2023 · Sep 30 | $4.1M | — | 85.4% | −$157.7M | −$179.5M | — | -1.08 | −$145.2M | $431K | −$145.7M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $502.1M | 95.8% | −$523.4M | −$732.9M | -146.0% | -3.78 | −$445.9M | $1.1M | −$447M | $48.3M | — |
| FY2024 · to Dec 31 | $221.9M | 98.3% | −$593M | −$543.3M | -244.9% | -2.88 | −$520.7M | $933K | −$521.7M | $0 | — |
| FY2023 · to Dec 31 | $9.3M | 73.7% | −$607.4M | −$653.3M | -7021.9% | -3.95 | −$527.7M | $1.3M | −$529M | $0 | — |
| FY2022 · to Dec 31 | $77.6M | 95.6% | −$512.2M | −$484.7M | -624.2% | -3.26 | −$419.5M | $4.8M | −$424.3M | $0 | — |
| FY2021 · to Dec 31 | $69.7M | 95.5% | −$576.6M | −$586.5M | -841.2% | -3.90 | −$497.9M | $13.2M | −$511.2M | $200M | — |
| FY2020 · to Dec 31 | $8.2M | — | −$474.5M | −$505.5M | -6127.9% | -3.80 | −$399.7M | $7.5M | −$407.2M | $75M | — |
Every number comes from BridgeBio Pharma, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.